adb-butinaca

ADB-BUTINACA, formally N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide, also known as ADBICA, is a synthetic cannabinoid of the indazole-3-carboxamide class belonging to the ADB (tert-leucinamide) pharmacophore series. This pharmacophore series has been consistently identified in SAR research as producing high-affinity CB1 receptor binding within the indazole scaffold. ADB-BUTINACA features a butyl chain at the N1 position of the indazole ring, distinguishing it from related compounds such as 5-FADB or ADB-FUBINACA, which carry longer or functionalised alkyl chains. This structural difference enables systematic comparison of N1-alkyl chain length effects within the ADB-indazole series — a key parameter in understanding cannabinoid receptor binding geometry. As a full agonist at CB1 receptors, ADB-BUTINACA activates Gi/Go-coupled signalling pathways including cAMP suppression, MAPK/ERK modulation, and ion channel regulation. Its in vitro metabolism has been characterised using hepatic microsomes, with hydroxylation and amide hydrolysis identified as primary routes. Metabolic products have been documented as forensic analytical reference materials. Our ADB-BUTINACA is produced to 99%+ purity, confirmed by HPLC-MS, NMR spectroscopy, and elemental analysis. A comprehensive Certificate of Analysis with full spectral documentation is provided with every order. Applications include CB1/CB2 receptor pharmacology, forensic toxicology reference standards, analytical method development, and ADB-series SAR research.